FrancophonIA/ELRC3.0 huggingface dataset:
English: Betmiga has not been studied in patients with end stage renal disease (GFR < 15 mL/min/1.73 m2 or patients requiring haemodialysis) and, therefore, it is not recommended for use in this patient population.
Danish: Betmiga er ikke undersøgt hos patienter med nyresygdom i slutstadiet (GFR < 15 ml/min/1,73 m2 eller patienter med behov for hæmodialyse) og bør derfor ikke anvendes til denne patientpopulation.
English: Betmiga 50 mg tablets
Danish: Betmiga 50 mg tabletter
English: Betmiga 25 mg tablets
Danish: Betmiga 25 mg tabletter
English: How to take Betmiga
Danish: Sådan skal du tage Betmiga
English: Betmiga has not been studied in patients with end stage renal disease (GFR < 15 mL/min/1.73 m2 or patients requiring haemodialysis) or severe hepatic impairment (Child-Pugh Class C) and it is therefore not recommended for use in these patient populations (see sections 4.4 and 5.2).
Danish: Betmiga er ikke undersøgt hos patienter med nyresygdom i slutstadiet (GFR < 15 ml/min/1,73 m2 eller patienter med behov for hæmodialyse) eller svært nedsat leverfunktion (Child-Pugh-klasse C) og bør derfor ikke anvendes til disse patientpopulationer (se pkt.
English: * Statistically significantly superior compared with placebo at the 0.05 level without multiplicity adjustment.
Danish: * Statistisk signifikant overlegent sammenlignet med placebo ved 0,05-niveauet uden multiplicitetsjustering.
English: - Swelling of the eyelid (eyelid oedema) - Swelling of the lip (lip oedema) - Swelling of the deeper layers of the skin caused by a build-up of fluid, which can affect any part of the body including the face, tongue or throat and may cause difficulty in breathing
Danish: - Hævet øjenlåg (øjenlågsødem) - Hævet læbe (læbeødem) - Hævelse af hudens dybere lag forårsaget af væskeophobning, hvilket kan påvirke alle dele af kroppen, herunder ansigt, tunge eller svælg, og kan forårsage åndedrætsbesvær (angioødem) - Små violette pletter på huden (purpura) - Betændelse i små blodkar, som hovedsagelig forekommer i huden (leukocytoklastisk vasculitis) - Manglende evne til at tømme blære helt (urinretention)
English: Betmiga is not recommended in patients with severe renal impairment (GFR 15 to 29 mL/min/1.73 m2) or patients with moderate hepatic impairment (Child-Pugh Class B) concomitantly receiving strong CYP3A inhibitors (see sections 4.2 and 4.4).
Danish: Betmiga bør ikke anvendes til patienter med svært nedsat nyrefunktion (GFR 15 til 29 ml/min/1,73 m2) eller patienter med moderat nedsat leverfunktion (Child-Pugh-klasse B), som samtidig får stærke CYP3A-hæmmere (se pkt.
English: Mean number of micturitions per 24 hours (FAS) (Co-primary)
Danish: Gennemsnitligt antal vandladninger pr. 24 timer (FAS) (co-primært)
English: Very rare side effects (may affect up to 1 in 10,000 people)
Danish: Meget sjældne bivirkninger (kan forekomme hos op til 1 ud af 10.000 personer)
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON FOR BOTTLES
Danish: MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE PAKNING TIL GLAS
English: Data are limited in patients with severe renal impairment (GFR 15 to 29 mL/min/1.73 m2); based on a pharmacokinetic study (see section 5.2) a dose reduction to 25 mg is recommended in this population.
Danish: Der er utilstrækkelige data for patienter med svært nedsat nyrefunktion (GFR 15 til 29 ml/min/1,73 m2); på grundlag af et farmakokinetisk studie (se pkt.
English: In females administered mirabegron at the 50 mg dose, the mean difference from placebo on QTcI interval at 5 hours post dose was 3.67 msec (upper bound of the one-sided 95% CI 5.72 msec).
Danish: Hos kvinder, som fik administreret mirabegron 50 mg, var den gennemsnitlige forskel i forhold til placebo i QTcIintervallet 3,67 msek.
English: Each tablet contains 25 mg of mirabegron.
Danish: Hver tablet indeholder 25 mg mirabegron.
English: Each tablet contains 50 mg of mirabegron.
Danish: Hver tablet indeholder 50 mg mirabegron.
English: # Statistically significantly superior compared with placebo at the 0.05 level with multiplicity adjustment.
Danish: # Statistisk signifikant overlegent sammenlignet med placebo ved 0,05-niveauet med multiplicitetsjustering.
English: ‡ Not statistically significantly superior compared to placebo at the 0.05 level with multiplicity adjustment.
Danish: ‡ Ikke statistisk signifikant overlegent sammenlignet med placebo ved 0,05-niveauet med multiplicitetsjustering.
English: Mean difference from placebo† (95% CI) p-value
Danish: Mirabegron 50 mg placebo† (95 % KI) p-værdi
English: Mean number of micturitions per 24 hours (FAS)
Danish: Gennemsnitligt antal vandladninger pr. 24 timer (FAS)
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING BOTTLE LABEL
Danish: MÆRKNING, DER SKAL ANFØRES PÅ DEN INDRE EMBALLAGE GLASETIKET
English: mesoridazine, haloperidol, and chlorpromazine; o anti-infectives such as pentamidine, moxifloxacin, erythromycin, and clarithromycin.
Danish: o medicin, som anvendes mod unormal hjerterytme, som f.eks. quinidin, sotalol, procainamid, ibutilid, flecainid, dofetilid og amiodaron; o medicin som anvendes mod høfeber; o antipsykotika (lægemidler mod psykisk sygdom), som f.eks. thioridazin, mesoridazin, haloperidol og chlorpromazin; o medicin, som anvendes mod infektion, som f.eks. pentamidin, moxifloxacin, erythromycin og clarithromycin.
English: Therefore, after reviewing all data, confusional state should be included in section 4.8 of the SmPC with frequency unknown.
Danish: Derfor bør konfusionsstatus efter gennemgang af alle data være inkluderet i pkt.
English: Mean level of urgency (FAS) (Secondary)
Danish: Gennemsnitlig grad af imperiøs vandladning (FAS) (sekundært)
English: Nervous system disorders
Danish: Nervesystemet Hovedpine* Svimmelhed*
English: In males, the difference was 2.89 msec (upper bound of the one-sided 95% CI 4.90 msec).
Danish: (den øvre grænse for det ensidede 95 % KI var 4,90 msek.).
English: Package leaflet: Information for the patient Betmiga 25 mg prolonged-release tablets Betmiga 50 mg prolonged-release tablets mirabegron
Danish: Indlægsseddel: Information til patienten Betmiga 25 mg depottabletter
English: 100 mg, the upper bound of the one-sided 95% confidence interval did not exceed 10 msec at any time point for the largest time-matched mean difference from placebo in the QTcI interval.
Danish: på noget tidspunkt for den største tidsmatchede gennemsnitlige forskel i forhold til placebo i QTcI-intervallet.
English: Astellas Pharma S.p.A. Tel: +39 (0)2 921381
Danish: Tel: +39 (0)2 921381
English: Urticaria Rash
Danish: Urticaria Udslæt
English: Betmiga 25 mg prolonged-release tablets Betmiga 50 mg prolonged-release tablets
Danish: Betmiga 25 mg depottabletter Betmiga 50 mg depottabletter.
English: Mean change from baseline† Mean difference from placebo† (95% CI) p-value
Danish: Gennemsnitlig baseline Gennemsnitlig ændring fra baseline† Gennemsnitlig forskel i forhold til placebo† (95 % KI) p-værdi
English: Betmiga 50 mg prolonged-release tablets mirabegron
Danish: Betmiga 50 mg depottabletter mirabegron
English: Betmiga 25 mg prolonged-release tablets mirabegron
Danish: Betmiga 25 mg depottabletter mirabegron
English: Betmiga 25 mg prolonged-release tablets Hypromellose 2910, 6 mPa.s Macrogol 8,000
Danish: Filmovertræk Betmiga 25 mg depottabletter Hypromellose 2910, 6 mPa.s Macrogol 8.000 Jernoxid, gult (E172) Jernoxid, rødt (E172)
English: Interval p-value † Least squares mean adjusted for baseline, gender and geographical region.
Danish: n Gennemsnitlig baseline Gennemsnitlig ændring fra baseline† Gennemsnitlig forskel i forhold til placebo† 95 % konfidensinterval p-værdi † Mindste kvadraters gennemsnit justeret for baseline, køn og geografisk region.
English: Patients with prior OAB antimuscarinic therapy who discontinued due to insufficient effect Mean number of incontinence episodes per 24 hours (FAS-I)
Danish: Patienter med tidligere antimuskarin OAB-behandling, hvis behandling blev seponeret som følge af utilstrækkelig virkning
English: Not recommended
Danish: Bør ikke anvendes
English: Astellas Pharma Europe B.V. Sylviusweg 62
Danish: Sylviusweg 62
English: Mean change from baseline† -0.93 Mean difference from placebo† -95% Confidence Interval
Danish: n Gennemsnitlig baseline Gennemsnitlig ændring fra baseline† Gennemsnitlig forskel i forhold til placebo† 95 % konfidensinterval
English: Mean change from baseline† -0.92 Mean difference from placebo† -95% Confidence Interval
Danish: Gennemsnitlig ændring fra baseline† Gennemsnitlig forskel i forhold til placebo† 95 % konfidensinterval p-værdi
English: Mean baseline Mean change from baseline† Mean difference from placebo†
Danish: Gennemsnitlig baseline Gennemsnitlig ændring fra baseline† Gennemsnitlig forskel i forhold til
English: Betmiga 50 mg prolonged-release tablets
Danish: Betmiga 50 mg filmovertrukne depottabletter
English: Betmiga 25 mg prolonged-release tablets
Danish: Betmiga 25 mg filmovertrukne depottabletter
English: Joint swelling
Danish: Mave-tarmkanalen
English: Woman of childbearing potential
Danish: Kvinder i den fertile alder
English: At a mirabegron dose of 200 mg, the QTcI interval did not exceed 10 msec at any time point in males, while in females the upper bound of the one-sided 95% confidence interval did exceed 10 msec between 0.5-6 hours, with a maximum difference from placebo at 5 hours where the mean effect was 10.42 msec (upper bound of the one-sided 95% CI 13.44 msec).
Danish: mellem 0,5 og 6 timer, med en maksimal forskel i forhold til placebo ved 5 timer, hvor den gennemsnitlige virkning var 10,42 msek.
English: With inhibitor
Danish: Med hæmmer
English: Further information on Apealea can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/apealea.
Danish: Yderligere information om Apealea findes på agenturets websted under: ema.europa.eu/medicines/human/EPAR/apealea.
English: By keeping this structure intact the cells cannot divide and they eventually die.
Danish: Når denne struktur forbliver intakt, kan cellerne ikke dele sig og vil til sidst dø.
English: Other information about Apealea
Danish: Andre oplysninger om Apealea
English: What measures are being taken to ensure the safe and effective use of Apealea?
Danish: Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Apealea?
English: As for all medicines, data on the use of Apealea are continuously monitored.
Danish: Som for alle lægemidler bliver data vedrørende brug af Apealea løbende overvåget.
English: The average length of time that patients lived without their disease coming back yet again was 10.3 months with Apealea, and 10.1 months with conventional paclitaxel.
Danish: Den gennemsnitlige tid, patienterne levede, uden at deres sygdom vendte tilbage igen, var 10,3 måneder med Apealea og 10,1 måneder med konventionel paclitaxel.
English: It belongs to the group of cancer medicines known as the ‘taxanes'.
Danish: Det hører til den gruppe af lægemidler mod kræft, der kaldes "taxaner".
English: It should not be interchanged with other medicines containing paclitaxel.
Danish: Det må ikke udskiftes med andre lægemidler indeholdende paclitaxel.
English: The European Medicines Agency considered that Apealea was as effective as conventional paclitaxel, and could be a valuable alternative in combination with carboplatin.
Danish: Det Europæiske Lægemiddelagentur fandt, at Apealea var lige så effektivt som konventionel paclitaxel, og at det kan være et værdifuldt alternativ i kombination med carboplatin.
English: For more information about using Apealea, see the package leaflet or contact your doctor or pharmacist.
Danish: For mere information om brug af Apealea, se indlægssedlen eller kontakt lægen eller apotekspersonalet.
English: stage of cell division in which the cell's internal ‘skeleton' is dismantled to allow the cell to divide.
Danish: stadium af cellernes deling, hvor det indvendige "skelet" i cellen adskilles, for at cellen kan dele sig.
English: The active substance in Apealea, paclitaxel, is a cancer medicine that has been used in the EU for many years.
Danish: Det aktive stof i Apealea, paclitaxel, er et kræftlægemiddel, der har været anvendt i EU i mange år.
English: Apealea contains the active substance paclitaxel.
Danish: Apealea indeholder det aktive stof paclitaxel.
English: While the new formulation might be associated with more infusion site reactions, and studies suggested stronger effects on blood cells and the gut, these were considered manageable and the overall benefits and risks are consistent with those of other paclitaxel medicines.
Danish: Selv om den nye formulering kan være forbundet med flere reaktioner på infusionsstedet, og undersøgelser tyder på større indvirkninger på blodceller og tarmen, blev disse anset for at kunne håndteres, og de samlede fordele og risici er i overensstemmelse med andre lægemidler med paclitaxel.
English: The dose of Apealea is 250 mg per square metre (calculated based on height and body weight) and is given by infusion over about 1 hour, once every 3 weeks, for 6 cycles of treatment.
Danish: Dosen af Apealea er 250 mg pr. kvadratmeter (beregnet på grundlag af højde og kropsvægt) og gives ved infusion i løbet af ca. 1 time én gang hver 3. uge i 6 behandlingsforløb.
English: Side effects reported with Apealea are carefully evaluated and any necessary action taken to protect patients.
Danish: Bivirkninger rapporteret for Apealea vurderes omhyggeligt, og der tages de nødvendige forholdsregler for at beskytte patienterne.
English: Supportive data from the study showed that the average time that patients lived after treatment was 25.7 months among those given Apealea and 24.8 months for those given conventional paclitaxel.
Danish: Understøttende data fra undersøgelsen viste, at den gennemsnitlige tid, patienterne levede efter behandlingen, var 25,7 måneder for dem, der fik Apealea, og 24,8 måneder for dem, der fik konventionel paclitaxel.
English: The medicine can only be obtained with a prescription and should be given under the supervision of a specialist in the treatment of cancer.
Danish: Lægemidlet udleveres kun på recept og bør kun gives under overvågning af en læge, der er specialiseret i brug af kræftmedicin.
English: An overview of Apealea and why it is authorised in the EU
Danish: En oversigt over Apealea, og hvorfor det er godkendt i EU
English: Apealea must not be used in patients who are breast feeding or those who already have low levels of neutrophils in the blood.
Danish: Apealea må ikke anvendes til patienter, som ammer, eller til patienter, der allerede har et lavt antal neutrofiler i blodet.
English: The Agency therefore decided that Apealea's benefits are greater than its risks and it can be authorised for use in the EU.
Danish: Agenturet konkluderede derfor, at fordelene ved Apealea opvejer risiciene, og at det kan godkendes til anvendelse i EU.
English: What is Apealea and what is it used for?
Danish: Hvad er Apealea, og hvad anvendes det til?
English: The most common side effects with Apealea (which may affect more than 1 in 10 people) are neutropenia (low numbers of white blood cells called neutrophils), stomach and gut disorders such as diarrhoea, nausea (feeling sick) and vomiting, peripheral neuropathy (nerve damage in hands and feet), joint and muscle pain, and reactions such as redness, soreness and inflammation of the veins at the site of infusion.
Danish: De hyppigste bivirkninger ved Apealea (som kan forekomme hos mere end 1 ud af 10 patienter) er neutropeni (lavt antal hvide blodlegemer kaldet neutrofiler), mave- og tarmlidelser såsom diarré, kvalme og opkastning, perifer neuropati (nerveskader i hænder og fødder), led- og muskelsmerter og reaktioner som rødme, ømhed og betændelse i venerne ved infusionsstedet.
English: Apealea is given along with a platinum-based medicine, carboplatin, to patients whose disease responds to platinum-based cancer medicines and has come back after initial treatment.
Danish: Apealea gives sammen med et platinbaseret lægemiddel, carboplatin, til patienter, hos hvem sygdommen reagerer på platinbaserede kræftlægemidler og er vendt tilbage efter den første behandling.
English: Apealea has been shown to be as effective as a conventional formulation of paclitaxel in one main study involving further treatment of 789 women whose ovarian, fallopian tube or peritoneal cancer had come back.
Danish: Det er påvist, at Apealea er lige så effektivt som en konventionel formulering af paclitaxel i én hovedundersøgelse, der omfattede yderligere behandling af 789 kvinder, hvis kræft i æggestokkene, æggelederne eller bughinden var vendt tilbage.
English: Why is Apealea authorised in the EU?
Danish: Hvorfor blev Apealea godkendt i EU?
English: What are the risks associated with Apealea?
Danish: Hvilke risici er der forbundet med Apealea?
English: Apealea is a cancer medicine used to treat women with cancer of the ovary or surrounding structures (the fallopian tube that connects the ovary to the womb, or the peritoneum, the membrane that lines the abdomen).
Danish: Apealea er et kræftlægemiddel, der anvendes til behandling af kvinder med kræft i æggestokkene eller omgivende strukturer (æggelederen, der forbinder æggestokken med livmoderen, eller bughinden, den indvendige membran, der beklæder bughulen).
English: Patients are also treated with a platinum-based medicine, carboplatin.
Danish: Patienterne behandles også med et platinbaseret lægemiddel, carboplatin.
English: The paclitaxel in Apealea is formulated in tiny particles, called micelles, to help it dissolve in the infusion solvent.
Danish: Paclitaxel i Apealea fremstilles i bittesmå partikler, kaldet miceller, for at det bedre kan opløses i infusionsvæsken.
English: Doses may be delayed or reduced by the doctor, or treatment may be stopped, if severe side effects occur; doses should also be reduced in patients with moderate or severe reduction in liver function.
Danish: Doserne kan udsættes eller nedsættes af lægen, eller behandlingen kan stoppes, hvis der opstår alvorlige bivirkninger.
English: Apealea is available as a powder to make up a solution for infusion (drip) into a vein.
Danish: Apealea fås som et pulver til fremstilling af en opløsning til infusion (drop) i en vene.
English: Patients also received a platinum-based cancer medicine, carboplatin.
Danish: Patienterne fik desuden et platinbaseret kræftlægemiddel, carboplatin.
English: For the full list of side effects of Apealea, see the package leaflet.
Danish: Den fuldstændige liste over bivirkninger ved Apealea fremgår af indlægssedlen.
English: How is Apealea used?
Danish: Hvordan anvendes Apealea?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Apealea have been included in the summary of product characteristics and the package leaflet.
Danish: Der er anført anbefalinger og forholdsregler i produktresuméet og indlægssedlen, som patienter og sundhedspersonale skal følge for at sikre risikofri og effektiv anvendelse af Apealea.
English: What benefits of Apealea have been shown in studies?
Danish: Hvilke fordele viser studierne, at der er ved Apealea?
English: Paclitaxel blocks a
Danish: Paclitaxel blokerer det
English: How does Apealea work?
Danish: Hvordan virker Apealea?
English: Solvent: 35 ml
Danish: Solvens: 35 ml
English: Packaging Content Package size Withdrawal period
Danish: Emballage Indhold Pakningsstørrelse
English: -1 Live avian infectious bronchitis virus, strain D388: 104.0 - 105.5 EID50*/dose * 50% egg infective dose
Danish: -1 Levende svækket aviær brinchitis virus, stamme 104.0 - 105.5 EID50*/dose * 50% æg-infektiøs dosis
English: Strength Pharmaceutical form
Danish: Lægemiddelform
English: Lyophilisate: 1,000 doses
Danish: Lyofilisat: 1.000 doser
English: -1 Lyophilisate and solvent for oculonasal suspension
Danish: Lyofilisat og solvens til okulonasal suspension
English: 10 lyophilisate cups + 10 solvent vials
Danish: 10 bæger med lyofilisat + 10 hætteglas med solvens
English: Chicken Oculonasal use Lyophilisate: cup (Alu/PP);
Danish: Lyofilisat: bæger (Alu/PP): Solvens: hætteglas (LDPE)
English: Target species
Danish: Særnavn
English: This summary was last updated in 07-2015.
Danish: Dette sammendrag blev sidst ajourført i 07-2015.
English: However, sexual stimulation is still needed.
Danish: Seksuel stimulering er dog stadig nødvendig.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Cialis on 12 November 2002.
Danish: Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Cialis den 12. november 2002.
English: The full EPAR for Cialis can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Danish: Den fuldstændige EPAR for Cialis findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: For Cialis to be effective in this condition, sexual stimulation is required.
Danish: For at Cialis kan være effektivt i denne tilstand, er seksuel stimulering nødvendig.
English: This is a summary of the European public assessment report (EPAR) for Cialis.
Danish: Dette dokument er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Cialis.
English: A doctor should consider the potential risks of sexual activity in men who have cardiovascular disease.
Danish: Lægen bør tage hensyn til den potentielle risiko ved seksuel aktivitet for mænd med kardiovaskulære sygdomme.
English: A risk management plan has been developed to ensure that Cialis is used as safely as possible.
Danish: Der er udarbejdet en risikostyringsplan for at sikre, at Cialis anvendes så sikkert som muligt.
English: One of these studies contained only diabetic men.
Danish: En af disse undersøgelser omfattede udelukkende mænd med sukkersyge.
English: It is available as tablets (2.5, 5, 10 and 20 mg).
Danish: Det fås som tabletter (2,5 mg, 5 mg, 10 mg og 20 mg).
English: The dose may be increased to 20 mg for men who do not respond to the 10 mg dose.
Danish: Dosis kan øges til 20 mg for mænd, som ikke reagerer på en dosis på 10 mg.
English: Other information about Cialis
Danish: Andre oplysninger om Cialis
English: The main measure of effectiveness was the improvement in symptoms after 12 weeks.
Danish: Behandlingens virkning blev hovedsagelig målt på forbedringen i symptomerne efter 12 uger.
English: Patients with severe liver problems or kidney problems should not take more than 10 mg in one dose.
Danish: Patienter med alvorlige lever- eller nyreproblemer bør ikke indtage mere end 10 mg i en enkelt dosis.
English: Once-a-day dosing is not recommended in patients with severe kidney problems, and should only be prescribed to patients with liver problems after a careful evaluation of the benefits and risks of taking the medicine.
Danish: En daglig dosis anbefales ikke til patienter med alvorlige nyreproblemer og bør kun ordineres til patienter med leverproblemer efter en nøje afvejning af fordelene og risiciene ved at tage lægemidlet.
English: The maximum recommended dosing frequency is once per day, but continuous daily use of 10 or 20 mg Cialis is not recommended.
Danish: Den anbefalede maksimale dosisfrekvens er én gang i døgnet, men langvarig daglig indtagelse af 10 eller 20 mg Cialis anbefales ikke.
English: For more information about treatment with Cialis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Danish: Hvis du ønsker yderligere oplysninger om behandling med Cialis, kan du læse indlægssedlen (også en del af denne EPAR) eller kontakte din læge eller dit apotek.
English: What measures are being taken to ensure the safe and effective use of Cialis?
Danish: Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Cialis?
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Cialis.
Danish: Det forklarer, hvordan Udvalget for Lægemidler til Mennesker (CHMP) vurderede lægemidlet og nåede frem til sin udtalelse til fordel for udstedelse af en markedsføringstilladelse og til sine anbefalinger om, hvordan Cialis skal anvendes.